Dr Alessio Cortellini is a consultant medical oncologist and a clinical scientist with a special interest on immunotherapy of cancer.
He graduated with honors at the University of L’Aquila in Italy, where he also completed his residency training in medical oncology. After leading the immunotherapy program at University of L’Aquila for more than a year he has moved to London in 2020.
Alessio currently works as visiting researcher at Imperial College London and as medical oncologist at Imperial College Healthcare NHS Trust, Hammersmith hospital, within the early phase clinical trial unit.
Dr Cortellini's efforts and research in immuno-oncology have been recognized with the Berlucchi Foundation award for the "Best Poster" presented at the XXI AIOM (Italian Association of Medical Oncology) National Congress and the Federico Calabresi award for the "Best publication of the year on a high impact factor international journal" at the 21st Edition of the "Grandangolo in Oncology" in 2019.
He was also named recipient of the third “Annual Young Investigator Award 2020”, by the editors of The Oncologist journal for a manuscript exploring the use of immune-checkpoint inhibitors in patients with pre-existing autoimmune diseases.
Alessio is an AIOM member and a member of the AIOM National Scientific Committee (Mandate: 2020-2021); he also is an ESMO (European Society of Medical Oncology) and SITC (Society for Immunotherapy of Cancer) member and served as external evaluator for the French National Cancer Institute (INCa).
He presented poster/oral communications in several national and international meetings (including ASCO, ESMO and AACR meetings) and has authored/co-authored more than 100 of full text publications in international medical journals.
Alessio also served as reviewer for many peer-reviewed international journals in the field of oncology and as lecturer for the Master in Immuno-oncology of the “Sapienza” University of Rome (Italy).
et al., 2021, Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma, European Journal of Cancer, Vol:157, ISSN:0959-8049, Pages:250-258
et al., 2021, Treatment-related toxicity and improved outcome from immunotherapy in hepatocellular cancer: Evidence from an FDA pooled analysis of landmark clinical trials with validation from routine practice., Eur J Cancer, Vol:157, Pages:140-152
et al., 2021, Response to letter entitled: Re: Predictive ability of a drug-based score in advanced non-small cell lung cancer patients receiving first-line immunotherapy., Eur J Cancer, Vol:155, Pages:315-316
et al., 2021, Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation., Cancer Immunol Immunother
et al., 2021, Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy., Ann Oncol